Pfizer (PFE) Gets Favorable Outcome for Axitinib from FDA Committee
Get Alerts PFE Hot Sheet
Price: $27.72 -0.79%
Overall Analyst Rating:
NEUTRAL ( Down)
Dividend Yield: 6.1%
Revenue Growth %: -21.1%
Overall Analyst Rating:
NEUTRAL ( Down)
Dividend Yield: 6.1%
Revenue Growth %: -21.1%
Join SI Premium – FREE
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) voted unanimously 13 to 0 that data for the investigational agent axitinib support a favorable benefit/risk profile for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of a first-line systemic therapy. The ODAC panel’s recommendation will be considered by the FDA when making its decision regarding Pfizer’s New Drug Application (NDA) for axitinib as a treatment for advanced RCC.
Approximately 58,000 new cases of RCC are diagnosed in the United States each year, and approximately 20 to 30 percent of these patients have advanced disease at the time of diagnosis. Around 13,000 individuals die of this tumor in the U.S. each year.
Approximately 58,000 new cases of RCC are diagnosed in the United States each year, and approximately 20 to 30 percent of these patients have advanced disease at the time of diagnosis. Around 13,000 individuals die of this tumor in the U.S. each year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pfizer (PFE) to trim its Haleon stake to 24%
- Cushman & Wakefield (CWK) Appoints Jennifer McPeek and Raj Vennam to Board of Directors
- Delcath Systems (DCTH) Appoints Martha S. Rook as Chief Operating Officer
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!